Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...